INCOME STATEMENT (Quarterly GAAP In millions $) |
(Oct 01 2024) Q3 2024 |
(Jul 02 2024) Q2 2024 |
(Apr 02 2024) Q1 2024 |
(Jan 02 2024) Q4 2024 |
(Oct 03 2023) Q3 2023 |
Revenue From Contract With Customer Including Assessed Tax |
865.47 |
904.04 |
891.22 |
|
830.21 |
Revenue From Contract With Customer Including Assessed Tax |
- |
- |
- |
|
- |
Total Revenue |
865.47 |
904.04 |
891.22 |
740.66 |
830.21 |
Cost of Goods and Services Sold |
- |
- |
- |
- |
- |
Gross
Profit |
865.47 |
904.04 |
891.22 |
740.66 |
830.21 |
Selling, Administration, Marketing |
310.94 |
317.28 |
320.93 |
292.61 |
301.66 |
Depriciation & Amortization |
25.30 |
24.96 |
24.76 |
23.26 |
22.84 |
Research & development |
- |
- |
- |
- |
- |
Business Combination, Acquisition Related Costs |
- |
- |
- |
- |
- |
Other operatinig exp. /-income |
488.53 |
496.13 |
500.36 |
485.26 |
479.94 |
Pre-Opening Costs |
7.01 |
6.98 |
5.88 |
1.03 |
6.74 |
Total operating costs including COS |
831.77 |
845.35 |
851.93 |
802.15 |
811.18 |
Operating income/-loss
|
33.70 |
58.69 |
39.29 |
-61.49 |
19.03 |
Other Deductions / - Income |
Interest expense |
- |
- |
- |
- |
- |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
- |
- |
- |
- |
- |
Loss (Income) from Equity Method Investments |
- |
- |
- |
- |
- |
Foreign Currency Transaction (Gain) Loss |
- |
- |
- |
- |
- |
Allowances, Health Care Trust Fund And Other |
- |
- |
- |
- |
- |
Unexpected (Gain) Loss |
- |
- |
- |
- |
- |
Other loss/ -income |
0.00 |
0.00 |
0.00 |
-0.03 |
0.00 |
Interest And Other Nonoperating Income Expense |
1.87 |
2.35 |
1.76 |
- |
2.03 |
Total costs & expenses |
833.64 |
847.70 |
853.69 |
802.13 |
813.21 |
Income /-loss before income taxes |
31.84 |
56.34 |
37.53 |
-61.47 |
17.00 |
Income taxes expenses/-benefit |
1.84 |
3.90 |
4.34 |
-15.92 |
-0.94 |
Income after income taxes |
29.99 |
52.44 |
33.19 |
-45.55 |
17.95 |
Net income/-loss
of other equity |
- |
- |
0.00 |
- |
- |
Temporary Equity Issuance Costs |
- |
- |
- |
- |
- |
Income/-loss
from cont. Ops. |
29.99 |
52.44 |
33.19 |
-45.55 |
17.95 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
- |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
29.99 |
52.44 |
33.19 |
-45.55 |
17.95 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
29.99 |
52.44 |
33.19 |
-45.55 |
17.95 |
EBIT |
31.84 |
56.34 |
37.53 |
-61.47 |
17.00 |
EBITD |
57.13 |
81.30 |
62.29 |
-37.45 |
39.84 |
EBITDA |
57.13 |
81.30 |
62.29 |
-37.45 |
39.84 |